Announced Thu, 9 Apr · 10:51 IST
Routine dematerialisation compliance certificate for Q4 FY2026
Compliance View source PDF
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-1.2%1-day move
₹1116.95
prior close
₹1109.30
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.0+0.2+0.1-0.1-1.2-3.2-2.2-2.9+0.1-5.3+0.2+8.1-22.3-13.9
Up moveDown movePending
AI summary
Natco Pharma's registrar (Venture Capital and Corporate Investments) submitted a routine certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026. It confirms that physical shares received for dematerialisation were cancelled and the depositories (NSDL and CDSL) were updated as the registered owner within 15 days. This is a standard quarterly compliance filing with no operational or financial details.
Likely market impact
Routine administrative compliance filing; no material impact on shareholders or stock price.